Hydromorphone is commonly used in hospital emergency rooms to treat patients with migraines; however, the drug is less effective than the drug prochlorperazine used with diphenhydramine, according to research.
Hydromorphone is commonly used in hospital emergency rooms to treat patients with migraines; however, the drug is less effective than the drug prochlorperazine used with diphenhydramine, according to research.
The study, published in the American Academy of Neurology, included 127 individuals who went to 2 emergency departments in New York due to their migraine. Half of the total study group received hydromorphone and half received prochlorperazine. Over a 48-hour period, the researchers considered how many participants sustained headache relief—defined as having a mild headache or no headache 2 hours following taking the drug and maintaining that level for 48 hours without additional medication.
“People go to US emergency departments 1.2 million times a year with migraine, and the opioid drug hydromorphone is used in 25% of these visits, yet there have been no randomized, high-quality studies on its use for acute migraine,” study author Benjamin W. Friedman, MD, MS, of Albert Einstein College of Medicine, said in a statement.
Following the 48 hours, 37 of 62 people (60%) who received prochlorperazine sustained headache relief, while 20 of the 64 people (31%) who received hydromorphone sustained headache relief. Additionally, 31% of patients who received hydromorphone asked for a second dose during the 48 hours while only 8% of those who received prochlorperazine asked for another dose. Also, 36% of patients who received hydromorphone requested other pain-reliever drugs, compared with 6% of the prochlorperazine group.
“While this study demonstrates the overwhelming superiority of prochlorperazine over hydromorphone for initial treatment of acute migraine, the results do not suggest that treatment with IV opioids leads to long-term addiction,” the authors wrote. “In addition, the results should not be used to avoid the use of opioids for people who have not responded well to anti-dopaminergic drugs.”
The researchers also considered whether the use of an opioid drug led to an addiction through returned visits to the emergency room. However, the study was limited because participants were required to have not used opioids in the previous month and have to history of addiction to opioids. Therefore, the participants may have already been at a decreased risk rate for opioid addiction than the general public.
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More